Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review

被引：25
|
作者：
Blayney, Douglas W. [1 ,3 ]
Schwartzberg, Lee [2 ]
机构：
[1] Stanford Canc Inst, Stanford, CA 75216 USA
[2] Univ Nevada, Renown Inst Canc, Reno, NV USA
[3] 875 Blake Wilbur Dr,Room CC-2219,M-C 6576, Stanford, CA 94305 USA
来源：
CANCER TREATMENT REVIEWS | 2022年 / 109卷
关键词：
Chemotherapy -induced neutropenia; G-CSF; Trilaciclib; Plinablin; Efbemalenograstim alpha; Eflapegrastim; INDUCED FEBRILE NEUTROPENIA; COLONY-STIMULATING FACTOR; RELATIVE DOSE INTENSITY; PER-CYCLE PEGFILGRASTIM; US CLINICAL-PRACTICE; BREAST-CANCER; PRIMARY PROPHYLAXIS; PLINABULIN PLIN; BIOSIMILAR FILGRASTIM; RECEIVING CHOP;
D O I：
10.1016/j.ctrv.2022.102427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：10
相关论文
共 50 条
  • [21] Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data
    Lalami, Yassine
    Klastersky, Jean
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 120 : 163 - 179
  • [22] Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
    Berto, Patrizia
    Bellone, Marco
    Sabinot, Alice
    Pinto, Carmine
    Martino, Massimo
    Generali, Daniele
    Carriero, Pier Luigi
    Sanna, Maria Domenica
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 1 - 12
  • [23] Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
    Hashiguchi, Yasunori
    Kasai, Mari
    Fukuda, Takeshi
    Ichimura, Tomoyuki
    Yasui, Tomoyo
    Sumi, Toshiyuki
    ANTI-CANCER DRUGS, 2015, 26 (10) : 1054 - 1060
  • [24] Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies
    Li, Yanli
    Klippel, Zandra
    Shih, Xiaolong
    Reiner, Maureen
    Wang, Hong
    Page, John H.
    SUPPORTIVE CARE IN CANCER, 2016, 24 (10) : 4377 - 4383
  • [25] ZarzioA®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
    Nahon, Sophie
    Rastkhah, Mansour
    Ben Abdelghani, Meher
    Soumoudronga, Ravaka-Fatoma
    Gasnereau, Isabelle
    Labourey, Jean-Luc
    SUPPORTIVE CARE IN CANCER, 2016, 24 (05) : 1991 - 1998
  • [26] Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
    Gascon, Pere
    Aapro, Matti
    Ludwig, Heinz
    Bokemeyer, Carsten
    Boccadoro, Mario
    Turner, Matthew
    Denhaerynck, Kris
    MacDonald, Karen
    Abraham, Ivo
    SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 911 - 925
  • [27] Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity
    Cho, Hyun-Woong
    Lee, Sanghoon
    Min, Kyung-Jin
    Hong, Jin Hwa
    Song, Jae Yun
    Lee, Jae Kwan
    Lee, Nak Woo
    Kim, Tak
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 20
  • [28] Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
    Perez, Aleymi M.
    Haberland, Nicole I.
    Miteva, Mariya
    Wikramanayake, Tongyu C.
    CURRENT ONCOLOGY, 2024, 31 (09) : 5709 - 5721
  • [29] Characterizing Chemotherapy-Induced Neutropenia and Monocytopenia Through Mathematical Modelling
    Cassidy, Tyler
    Humphries, Antony R.
    Craig, Morgan
    Mackey, Michael C.
    BULLETIN OF MATHEMATICAL BIOLOGY, 2020, 82 (08)
  • [30] Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children
    Kim, Heeyeon
    Mousa, Shaker A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (08) : 977 - 986
12345